Beam Therapeutics (BEAM) Expected to Announce Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.1064) per share and revenue of $16.37 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Thursday, May 7th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.12. Beam Therapeutics had a negative net margin of 39.66% and a negative return on equity of 29.00%. The firm had revenue of $31.74 million during the quarter, compared to analyst estimates of $10.98 million. During the same quarter in the prior year, the firm posted ($1.23) EPS. Beam Therapeutics’s revenue was up 323.2% compared to the same quarter last year. On average, analysts expect Beam Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Stock Down 0.1%

BEAM stock opened at $25.07 on Tuesday. The firm’s 50-day moving average is $31.12 and its two-hundred day moving average is $29.26. The company has a market capitalization of $2.58 billion, a price-to-earnings ratio of -36.87 and a beta of 2.18. Beam Therapeutics has a 52 week low of $15.60 and a 52 week high of $38.26. The company has a current ratio of 16.99, a quick ratio of 16.99 and a debt-to-equity ratio of 0.09.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Sanford C. Bernstein dropped their target price on Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Tudor Pickering set a $39.00 price objective on Beam Therapeutics in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Beam Therapeutics in a report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Beam Therapeutics in a research note on Tuesday, July 7th. Finally, Bank of America reissued a “buy” rating and issued a $47.00 price target on shares of Beam Therapeutics in a report on Wednesday, July 8th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Beam Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $46.85.

Insider Activity at Beam Therapeutics

In other news, insider Fmr Llc sold 251,488 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the completion of the sale, the insider directly owned 854,583 shares of the company’s stock, valued at $30,132,596.58. This trade represents a 22.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. ARK Investment Management LLC lifted its holdings in shares of Beam Therapeutics by 12.9% during the fourth quarter. ARK Investment Management LLC now owns 12,467,189 shares of the company’s stock valued at $345,590,000 after purchasing an additional 1,428,355 shares during the last quarter. State Street Corp raised its holdings in Beam Therapeutics by 30.4% during the 4th quarter. State Street Corp now owns 5,228,529 shares of the company’s stock worth $144,935,000 after buying an additional 1,219,871 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Beam Therapeutics by 237.5% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,665,385 shares of the company’s stock valued at $40,419,000 after buying an additional 1,171,977 shares in the last quarter. Marshall Wace LLP purchased a new stake in Beam Therapeutics during the fourth quarter valued at about $26,218,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of Beam Therapeutics in the second quarter worth about $10,101,000. 99.68% of the stock is owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.